Last $1.37 USD
Change Today +0.01 / 0.74%
Volume 182.8K
STXS On Other Exchanges
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

stereotaxis inc (STXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/12/14 - $6.34
52 Week Low
12/16/14 - $1.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STEREOTAXIS INC (STXS)

Related News

No related news articles were found.

stereotaxis inc (STXS) Related Businessweek News

No Related Businessweek News Found

stereotaxis inc (STXS) Details

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive Robotic Navigation System, which offer navigation and stability for the diagnostic and ablation devices that assist in delivery of ablations. The company also offers Odyssey solution, which provides integrated real-time information solution to manage, control, record, and share procedures across networks; acquires a real-time remote view of the lab capturing synchronized procedure data for the review of events during cases; enable physicians to access recorded cases and create snapshots following procedures for clinical reporting, auditing, and presenting; and enables physicians to establish a master archive of procedures performed in the lab. In addition, it provides disposables and other accessories, such as Cardiodrive or QuikCAS automated catheter advancement disposables for the advancement of electrophysiology catheters; CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters; and Titan and Pegasus coronary guide wires for cardiology procedures. Further, the company offers V-CAS catheter and V-CAS Deflect integrated catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. It has strategic alliances with Siemens AG Medical Solutions, Philips Medical Systems, and Biosense Webster, Inc. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

123 Employees
Last Reported Date: 03/27/14
Founded in 1990

stereotaxis inc (STXS) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $370.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $192.5K
Head of Asia Business and Senior Vice Preside...
Total Annual Compensation: $285.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $270.0K
Vice President of Human Resources
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2013.

stereotaxis inc (STXS) Key Developments

Stereotaxis Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Stereotaxis Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total revenue was $8,854,101 compared to $10,821,444 in the prior year quarter. Operating loss was $1,179,573 compared to $1,068,843 in the prior year quarter. Net income was $22,670, or $0.00 per basic and diluted share compared to a net loss of $56,868,442 or $4.49 per basic and diluted share reported in the same period a year ago. Cash burn for the third quarter of 2014 was $2.3 million, compared to $1.6 million for the third quarter of 2013. During the quarter, the Company recognized revenue of $0.9 million on completion of five Niobe ES system installations and one Niobe ES system upgrade, $1.1 million in Odyssey(R) solution sales and $0.2 million in Vdrive system sales. Recurring revenue was $6.7 million in the third quarter, compared to $6.4 million in the prior year quarter and $6.9 million in the second quarter 2014. Procedures increased 2% from the same quarter last year and declined 6% sequentially. For the nine months, the company's total revenue was $25,256,308 compared to $28,963,055 in the prior year quarter. Operating loss was $5,698,197 compared to $6,416,336 a year ago. Net loss was $6,058,656 or $0.31 per basic and diluted share, compared to a net loss of $64,795,382 or $6.72 per basic and diluted share, reported in the same period a year ago.

Stereotaxis Inc. to Report Q3, 2014 Results on Nov 05, 2014

Stereotaxis Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on Nov 05, 2014

Stereotaxis Inc., Q3 2014 Earnings Call, Nov 05, 2014

Stereotaxis Inc., Q3 2014 Earnings Call, Nov 05, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STXS:US $1.37 USD +0.01

STXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $2.45 USD -0.1797
Bovie Medical Corp $3.41 USD -0.09
Hansen Medical Inc $0.59 USD -0.0248
Uroplasty Inc $2.40 USD -0.11
Vision Sciences Inc/DE $1.00 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation STXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEREOTAXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at